• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ROCURONIUM Drug Record

  • Summary
  • Interactions
  • Claims
  • ROCURONIUM chembl:CHEMBL1201244 Approved

    Alternate Names:

    ROCURONIUM
    ZEMURON®
    ESMERON®
    ORG-9426
    chemidplus:143558-00-3
    chembl:CHEMBL1201244
    pubchem.compound:441290
    drugbank:00728
    rxcui:68139

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications muscle relaxant
    Drug Class muscle relaxants, skeletal
    Year of Approval 1994
    (1 More Sources)

    Publications:

    Milchert et al., 2009, Skeletal muscle relaxants inhibit rat tracheal smooth muscle tone in vitro., J. Physiol. Pharmacol.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Mei Y et al., 2015, Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients., J Clin Pharmacol
    Jonsson Fagerlund et al., 2009, Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor., Anesthesiology
    Liu et al., 2008, Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors., Anesth. Analg.
    Jonsson et al., 2006, Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade., Anesthesiology
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Min et al., 2000, Nondepolarizing neuromuscular blockers inhibit the serotonin-type 3A receptor expressed in Xenopus oocytes., Anesth. Analg.
    Costa ACC et al., 2017, The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries., Eur J Clin Pharmacol
  • ROCURONIUM   CHRNA2

    Interaction Score: 5.15

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name rocuronium bromide,Esmeron, Zemuron, Eslax
    Novel drug target Established target

    PMIDs:
    19417616 18633030 16931985 11752352 17016423 17139284


    Sources:
    TdgClinicalTrial TEND TTD

  • ROCURONIUM   SLCO1A2

    Interaction Score: 4.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28409297


    Sources:
    PharmGKB

  • ROCURONIUM   CHRM2

    Interaction Score: 1.01

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name rocuronium bromide,Esmeron, Zemuron, Eslax
    Novel drug target Established target

    PMIDs:
    20400785 17016423 17139284


    Sources:
    TdgClinicalTrial TEND

  • ROCURONIUM   HTR3A

    Interaction Score: 0.47

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name rocuronium bromide,Esmeron, Zemuron, Eslax
    Novel drug target Established target

    PMIDs:
    10648343


    Sources:
    TdgClinicalTrial

  • ROCURONIUM   SLCO1B1

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25279974


    Sources:
    PharmGKB

  • ROCURONIUM   ABCB1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25279974


    Sources:
    PharmGKB

  • TEND: ROCURONIUM

    • Version: 01-August-2011

    Alternate Names:
    ROCURONIUM Primary Drug Name

    Drug Info:
    Year of Approval 1994
    Drug Class muscle relaxants, skeletal

    Publications:

  • TdgClinicalTrial: ROCURONIUM

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications muscle relaxant
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: rocuronium

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Mei Y et al., 2015, Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients., J Clin Pharmacol
    Costa ACC et al., 2017, The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries., Eur J Clin Pharmacol

  • TTD: Rocuronium

    • Version: 2020.06.01

    Alternate Names:
    D0L5CZ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201244

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21